Precision Engineering of Extracellular Vesicles as Programmable Carriers for mRNA Therapeutics
International Journal of Nanomedicine · 2026-05 · Volume 21 · 1-30
DOI: 10.2147/ijn.s595161 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2026-05. Verfasst von Hyejoo Yoon und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, CHA University, Seongnam-si, Gyeonggi-do, Republic of Korea. Hauptthemen laut MEDLINE: Extracellular Vesicles, RNA, Messenger, Drug Carriers. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 239 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Messenger RNA (mRNA) therapeutics have rapidly evolved into a transformative modality for treating infectious diseases, cancer, and genetic disorders; however, the clinical translation of these therapeutics remains limited by the need for safe, efficient, and tissue-specific delivery vehicles. Subsequently, extracellular vesicles (EVs) have emerged as a promising next-generation platform due to the associated endogenous biogenesis, intrinsic biocompatibility, low immunogenicity, and natural ability to traverse biological barriers. Thus, this review provides a comprehensive evaluation of the major engineering strategies enabling EV-based mRNA delivery, including exogenous loading methods, endogenous genetic engineering, physical microenvironment-driven enhancement, and hybrid EV-synthetic nanoparticle systems. Moreover, this review summarizes advances in electroporation, lipid-mediated fusion, and chemical/physical loading techniques; programmable endogenous loading platforms leveraging EV-sorting proteins and RNA-binding domains; cargo release mechanisms employing self-cleaving, protease-sensitivity, and optogenetic modules; device- and substrate-based approaches that modulate EV biogenesis and cargo composition. We further highlight emerging hybrid EV systems-particularly fusogenic cubosome-EV constructs-that achieve near-quantitative mRNA encapsulation and improved biodistribution, including enhanced penetration across the blood-brain barrier. Finally, we discuss technological bottlenecks and translational considerations, including scalability, batch variability, long-term mRNA stability, and regulatory challenges associated with biologically derived carriers. Collectively, this review outlines the current landscape and future directions for precision engineering of EVs as programmable, clinically viable carriers for mRNA therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, CHA University, Seongnam-si, Gyeonggi-do, Republic of Korea.
- College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
- College of Pharmacy, Chungbuk National University, Cheongju, Republic of Korea.
- CHA Advanced Research Institute, Seongnam-si, Gyeonggi-do, Republic of Korea.
ORCID-Profile: Hyejoo Yoon, Kyung Taek Oh
Zitieren
APA
Yoon, H., Lee, G., Jo, J., Koo, J., Kim, E. H., Choi, H. J., Jung, S., Shin, Y., Oh, K. T., & Lim, C. (2026). Precision Engineering of Extracellular Vesicles as Programmable Carriers for mRNA Therapeutics. International Journal of Nanomedicine, Volume 21, 1-30. https://doi.org/10.2147/ijn.s595161
Vancouver
Yoon H, Lee G, Jo J, Koo J, Kim EH, Choi HJ, et al. Precision Engineering of Extracellular Vesicles as Programmable Carriers for mRNA Therapeutics. International Journal of Nanomedicine. 2026;Volume 21:1-30. doi:10.2147/ijn.s595161
BibTeX
@article{Yoon2026,
author = {Yoon, Hyejoo and Lee, Gyuwon and Jo, Junyeong and Koo, Jain and Kim, Eun-Hee and Choi, Hyun Jin and Jung, Sangyong and Shin, Yuseon and Oh, Kyung Taek and Lim, Chaemin},
title = {Precision Engineering of Extracellular Vesicles as Programmable Carriers for mRNA Therapeutics},
journal = {International Journal of Nanomedicine},
year = {2026},
volume = {Volume 21},
pages = {1--30},
doi = {10.2147/ijn.s595161}
}
EUVIMED